Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug

Rabiya S Tuma

Journal of the National Cancer Institute 2011 February 2, 103 (3): 170-1, 177

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Drug discovery: How melanomas bypass new therapy. David Solit, Charles L Sawyers Nature 2010 December 16, 468 (7326): 902-3

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Hubing Shi, Xiangju Kong, Antoni Ribas, Roger S Lo Cancer Research 2011 August 1, 71 (15): 5067-74

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Cory M Johannessen, Jesse S Boehm, So Young Kim, Sapana R Thomas, Leslie Wardwell, Laura A Johnson, Caroline M Emery, Nicolas Stransky, Alexandria P Cogdill, Jordi Barretina, Giordano Caponigro, Haley Hieronymus, Ryan R Murray, Kourosh Salehi-Ashtiani, David E Hill, Marc Vidal, Jean J Zhao, Xiaoping Yang, Ozan Alkan, Sungjoon Kim, Jennifer L Harris, Christopher J Wilson, Vic E Myer, Peter M Finan, David E Root, Thomas M Roberts, Todd Golub, Keith T Flaherty, Reinhard Dummer, Barbara L Weber, William R Sellers, Robert Schlegel, Jennifer A Wargo, William C Hahn, Levi A Garraway Nature 2010 December 16, 468 (7326): 968-72

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Fei Su, William D Bradley, Qiongqing Wang, Hong Yang, Lizhong Xu, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Min Jung Kim, Kerstin Trunzer, Richard J Lee, Kathleen Schostack, Jade Carter, Thomas Albert, Soren Germer, Jim Rosinski, Mitchell Martin, Mary Ellen Simcox, Brian Lestini, David Heimbrook, Gideon Bollag Cancer Research 2012 February 15, 72 (4): 969-78

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Judith Müller, Oscar Krijgsman, Jennifer Tsoi, Lidia Robert, Willy Hugo, Chunying Song, Xiangju Kong, Patricia A Possik, Paulien D M Cornelissen-Steijger, Marnix H Geukes Foppen, Kristel Kemper, Colin R Goding, Ultan McDermott, Christian Blank, John Haanen, Thomas G Graeber, Antoni Ribas, Roger S Lo, Daniel S Peeper Nature Communications 2014 December 15, 5: 5712

Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. Fang Liu, Juxiang Cao, Jinxiang Wu, Kayleigh Sullivan, James Shen, Byungwoo Ryu, Zhixiang Xu, Wenyi Wei, Rutao Cui Journal of Investigative Dermatology 2013, 133 (8): 2041-9

Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Li, Xue-Qian Gong, Sean Buchanan, James R Henry, James J Starling, Sheng-Bin Peng Journal of Biological Chemistry 2012 August 10, 287 (33): 28087-98

Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. Martin Michaelis, Florian Rothweiler, Thomas Nerreter, Marijke van Rikxoort, Richard Zehner, Wilhelm G Dirks, Michael Wiese, Jindrich Cinatl BMC Research Notes 2014 October 10, 7: 710

The genesis of Zelboraf: targeting mutant B-Raf in melanoma. Matthew J Davis, Joseph Schlessinger Journal of Cell Biology 2012 October 1, 199 (1): 15-9

Inhibition of mutated BRAF in melanoma. Taegyun Kim, Jihyun Kim, Min-Geol Lee New England Journal of Medicine 2010 December 2, 363 (23): 2261; author reply 2261-2

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Getting around PLX4032: studies turn up unusual mechanisms of resistance to melanoma drug

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips